Esophageal varices are dilated submucosal veins in the distal esophagus that develop when portal hypertension forces blood through portosystemic collateral pathways. Approximately 30% to 40% of patients with compensated cirrhosis have varices at diagnosis, and without prophylaxis, 25% to 30% of those with medium or large varices will experience a hemorrhagic episode within two years. Each bleeding episode carries a 15% to 25% mortality rate, with 6-week mortality reaching 10% to 20% depending on disease severity. This makes variceal hemorrhage one of the most lethal GI emergencies a nurse will manage. Recognizing the early hemodynamic signs, understanding pharmacologic and endoscopic interventions, and knowing what to prioritize during an active bleed are essential competencies tested on the NCLEX and used daily in ICU, med-surg, and hepatology settings.
| Feature | Detail |
|---|---|
| Definition | Dilated submucosal veins in the distal esophagus formed by portosystemic collateral circulation secondary to portal hypertension |
| Primary cause | Portal hypertension, most commonly from cirrhosis |
| HVPG threshold for varices | Greater than or equal to 10 mmHg (clinically significant portal hypertension) |
| HVPG threshold for bleeding | Greater than or equal to 12 mmHg |
| Classification | F1 (small, straight), F2 (medium, tortuous, less than 1/3 lumen), F3 (large, more than 1/3 lumen) |
| First bleed risk (untreated) | 5% per year for small varices; 15% per year for large varices |
| Rebleeding rate | Up to 70% within 1 year without secondary prophylaxis |
| Mortality per bleed | 15%–25% per episode; 6-week mortality 10%–20% |
| Primary prophylaxis | Non-selective beta-blockers (carvedilol preferred) or EVL for NSBB-intolerant patients |
| Acute hemorrhage first-line | Vasoactive drugs (octreotide or terlipressin) + emergent EVL + prophylactic antibiotics |
| Nursing priority | Airway protection first, hemodynamic stabilization, restrictive transfusion (Hb target 7 g/dL) |
Pathophysiology: portal hypertension and variceal formation
Esophageal varices develop through a predictable hemodynamic sequence that begins with increased resistance to portal blood flow and ends with rupture of thin-walled collateral vessels. Understanding this pathway connects directly to the rationale behind every treatment intervention.
Increased intrahepatic resistance. In cirrhosis, fibrotic remodeling and regenerative nodules compress the hepatic sinusoids and increase resistance to portal blood flow. This structural component accounts for approximately 70% of the increased portal pressure. The remaining 30% comes from a functional component – increased intrahepatic vascular tone driven by endothelin-1 overproduction and reduced nitric oxide availability within the liver.
Splanchnic vasodilation. As portal pressure rises, the splanchnic (mesenteric) vascular bed responds by overproducing vasodilators – primarily nitric oxide, prostaglandins, and glucagon. This progressive splanchnic arterial vasodilation increases blood flow into the portal system, further raising portal pressure. The result is a self-amplifying cycle: higher portal pressure causes more vasodilation, which drives more blood into an already congested portal system.
Portosystemic collateral formation. When the hepatic venous pressure gradient (HVPG) exceeds 10 mmHg – defined as clinically significant portal hypertension (CSPH) – blood seeks alternative pathways back to systemic circulation. The most clinically important collaterals form at the gastroesophageal junction, where the left gastric (coronary) vein connects with the esophageal venous plexus draining into the azygos system. These dilated submucosal veins in the distal esophagus are esophageal varices.
Variceal wall tension and rupture. The risk of variceal rupture depends on wall tension, governed by LaPlace’s law: wall tension = (transmural pressure x variceal radius) / wall thickness. As portal pressure increases (raising transmural pressure), varices enlarge (increasing radius), and the vessel wall thins. When wall tension exceeds the elastic limit of the vessel, rupture occurs. This is why bleeding risk correlates with variceal size and HVPG – specifically, varices rarely bleed when HVPG is below 12 mmHg.
Grading and classification
Endoscopy is the gold standard for identifying and grading esophageal varices. The two most widely used classification systems are the Japanese Research Society for Portal Hypertension grading (F1 through F3) and the simplified North Italian Endoscopic Club (NIEC) system (small vs. large). In clinical practice and AASLD/Baveno VII guidelines, the small versus large distinction is most commonly referenced.
Small varices (F1). Straight veins that minimally protrude into the esophageal lumen. These flatten with insufflation during endoscopy. Annual bleeding risk is approximately 5% per year.
Medium varices (F2). Tortuous, slightly enlarged veins occupying less than one-third of the esophageal lumen. They do not flatten with insufflation. Presence of red wale signs elevates bleeding risk significantly.
Large varices (F3). Coiling veins that occupy more than one-third of the esophageal lumen. Annual first-bleed risk is approximately 15% per year. These require primary prophylaxis regardless of other factors.
Red wale signs
Red wale markings are the most important endoscopic risk markers for impending hemorrhage. These appear as longitudinal red streaks on the variceal surface representing microtelangiectasias in the variceal wall. Additional high-risk endoscopic features include cherry red spots (small, discrete red dots), hematocystic spots (blood-filled blisters – the highest-risk finding), and diffuse mucosal redness over the varix. The combination of large variceal size plus red wale signs in a Child-Pugh C patient represents the highest bleeding risk category.
Screening recommendations
Per Baveno VII consensus, patients with compensated advanced chronic liver disease (cACLD) who have liver stiffness below 20 kPa and platelet count above 150,000/microL have a very low risk of high-risk varices and can avoid screening endoscopy. These patients are monitored with annual transient elastography and platelet counts instead. All other patients with cirrhosis require screening upper endoscopy, repeated every two to three years for compensated disease and annually for decompensated disease.
Nursing assessment
Assessment priorities for a patient with known or suspected esophageal varices depend on whether the patient is stable (surveillance phase) or actively bleeding.
Stable patient assessment
For patients with known varices who are not bleeding, nursing assessment focuses on identifying risk factors for decompensation and monitoring for early signs of hemorrhage:
- History: Etiology of liver disease (alcohol, hepatitis B or C, NAFLD), prior variceal bleeding episodes, current medications (beta-blocker adherence, NSAIDs – which increase bleeding risk), alcohol use status
- Hepatic function indicators: Ascites presence and severity, hepatic encephalopathy grade, jaundice, Spider angiomata – these contribute to Child-Pugh scoring (A, B, or C) which directly predicts bleeding risk and mortality
- Baseline labs: Platelets (thrombocytopenia below 150,000 suggests portal hypertension), INR (coagulopathy), albumin (synthetic function), creatinine (renal function – relevant for hepatorenal syndrome risk), hemoglobin baseline
- MELD score awareness: The Model for End-Stage Liver Disease uses bilirubin, INR, and creatinine to predict 90-day mortality. A MELD score above 18 significantly increases post-bleed mortality
Active bleeding assessment
When a patient with esophageal varices presents with hematemesis (bright red or coffee-ground emesis) or melena, the assessment shifts to rapid hemodynamic evaluation:
- Airway first. Massive upper GI hemorrhage carries a high aspiration risk. Assess level of consciousness, gag reflex, and airway patency. Patients with altered mental status (from hepatic encephalopathy or hemorrhagic shock) or massive hematemesis often require emergent intubation before any other intervention.
- Hemodynamic status. Heart rate (tachycardia above 100 bpm is often the earliest sign), blood pressure (systolic below 90 mmHg indicates class III or IV shock), mean arterial pressure (target above 65 mmHg), orthostatic vital signs if the patient can sit safely, capillary refill, and skin color/temperature.
- Hemorrhage volume estimation. Serial hemoglobin and hematocrit (note: initial values may be falsely normal in acute hemorrhage before equilibration), urine output (goal above 0.5 mL/kg/hr), and lactate level.
- Two large-bore IVs (16-gauge or larger) immediately. Send type and crossmatch, CBC, CMP, coagulation studies, and lactate with the initial draw.
Primary prophylaxis
Primary prophylaxis aims to prevent the first variceal bleed in patients with medium or large varices. The Baveno VII consensus (2021) and AASLD practice guidance both recommend two first-line options.
Non-selective beta-blockers
NSBBs reduce portal pressure by decreasing cardiac output (beta-1 blockade) and causing splanchnic vasoconstriction (beta-2 blockade). They reduce first-bleed risk from approximately 25% to 15% over two years.
- Carvedilol (6.25 mg daily, may titrate to 12.5 mg daily) is the preferred NSBB per Baveno VII due to its additional alpha-1 blocking activity, which reduces intrahepatic vascular resistance. Carvedilol produces a greater reduction in HVPG than propranolol or nadolol. Baveno VII recommends carvedilol for all compensated patients with clinically significant portal hypertension.
- Propranolol (20 mg twice daily, titrated to a resting heart rate of 55 to 60 bpm, maximum 320 mg/day) remains an alternative.
- Nadolol (40 mg daily, titrated similarly to heart rate target) is used when propranolol is not tolerated.
Nursing considerations for NSBB therapy: Monitor heart rate (hold if below 55 bpm), blood pressure (hold if systolic below 90 mmHg or MAP below 65 mmHg), and for signs of bronchospasm in patients with reactive airway disease. NSBBs are contraindicated in refractory ascites with severe hypotension, as they may worsen renal perfusion – this is the so-called “NSBB window” where beta-blockers help portal hypertension but harm systemic hemodynamics.
Endoscopic variceal ligation
EVL (banding) is recommended for patients with medium or large varices who have contraindications or intolerance to NSBBs. Bands are placed on the varices to necrose and obliterate them. Sessions are repeated every 2 to 4 weeks until variceal eradication, then surveillance endoscopy every 3 to 6 months. Post-banding, patients receive a proton pump inhibitor (such as lansoprazole 30 mg daily) until varices are obliterated to reduce band ulcer complications.
Acute variceal hemorrhage management
Acute variceal bleeding is a medical emergency requiring simultaneous resuscitation, pharmacotherapy, and endoscopic intervention. The sequence below reflects current AASLD and Baveno VII guidance.
Step 1: Airway and hemodynamic stabilization
Airway protection is the first priority. Patients with massive hematemesis, altered mental status, or hemodynamic instability should be intubated before endoscopy. Establish two large-bore peripheral IVs and begin crystalloid resuscitation. Blood transfusion follows a restrictive threshold – target hemoglobin of 7 g/dL, transfusing only to 7 to 9 g/dL. Over-transfusion raises portal pressure and increases rebleeding risk. Avoid aggressive volume resuscitation for the same reason.
Step 2: Vasoactive drug therapy
Vasoactive agents should be started as soon as variceal hemorrhage is suspected – before endoscopy, before lab confirmation, and ideally in the emergency department.
- Octreotide (most commonly used in the United States): 50 mcg IV bolus followed by a continuous infusion of 50 mcg/hr for 2 to 5 days. Octreotide inhibits splanchnic vasodilation and reduces portal blood flow.
- Terlipressin (a vasopressin analog, available internationally and FDA-approved in the US): 2 mg IV every 4 hours for the first 24 to 48 hours, then reduced to 1 mg IV every 4 hours. Terlipressin directly constricts splanchnic arterioles, reducing portal inflow. It is the only vasoactive agent shown to reduce mortality in variceal bleeding. Monitor for ischemic complications (mesenteric, cardiac, peripheral) and hyponatremia.
- Somatostatin (used in some European centers): 250 mcg IV bolus followed by 250 mcg/hr infusion.
Step 3: Prophylactic antibiotics
Antibiotics are started immediately – ideally before endoscopy – because bacterial infections occur in up to 50% of cirrhotic patients with GI bleeding and are an independent predictor of rebleeding and mortality. A 7-day course reduces the incidence of spontaneous bacterial peritonitis, bacteremia, and pneumonia.
- Ceftriaxone 1 g IV every 24 hours is the preferred agent for patients with advanced cirrhosis (Child-Pugh B or C) or in settings with high quinolone resistance.
- Norfloxacin 400 mg orally twice daily (or ciprofloxacin 500 mg IV twice daily for patients who cannot take oral medications) is an alternative for Child-Pugh A patients.
Step 4: Emergent endoscopy with EVL
Upper endoscopy should be performed within 12 hours of presentation. Erythromycin (250 mg IV, given 30 to 120 minutes before endoscopy) improves gastric visualization by promoting gastric emptying. EVL is the endoscopic treatment of choice – it has lower rebleeding rates, fewer complications, and faster variceal eradication than sclerotherapy. Successful hemostasis is achieved in approximately 90% of cases.
NG tube precaution: Nasogastric tube insertion is avoided in patients with known unligated esophageal varices due to the risk of mechanical trauma and hemorrhage provocation. If gastric decompression is required before endoscopy, the decision should be made by the endoscopy or critical care team with full awareness of the variceal status.
Step 5: Rescue therapies for refractory bleeding
Approximately 10% to 20% of variceal hemorrhages are refractory to standard pharmacologic and endoscopic therapy. Rescue options include:
- Balloon tamponade (Sengstaken-Blakemore tube or Minnesota tube). A temporary bridge measure that achieves hemostasis in approximately 90% of cases by direct compression of varices. It is a temporizing measure only – placement is limited to a maximum of 24 hours due to a high complication rate (20% to 60%), including esophageal necrosis, perforation, and aspiration. The patient must be intubated before insertion. Gastric balloon is inflated first (250 to 300 mL air), confirmed by X-ray, then traction is applied. The esophageal balloon is inflated only if gastric balloon tamponade fails. Continuous monitoring of balloon pressures and respiratory status is mandatory.
- Transjugular intrahepatic portosystemic shunt (TIPS). TIPS creates a low-resistance channel between the portal vein and the hepatic vein, decompressing the portal system. Preemptive (early) TIPS – placed within 24 to 72 hours – is recommended for high-risk patients (Child-Pugh B with active bleeding at endoscopy, or Child-Pugh C with a score of 10 to 13) and has been shown to improve survival and reduce treatment failure. Rescue TIPS is used when EVL and pharmacotherapy fail. The primary complication of TIPS is hepatic encephalopathy (occurring in 25% to 45% of patients) and shunt occlusion or stenosis, requiring surveillance Doppler studies.
Secondary prophylaxis
After surviving a first variceal bleed, patients face up to a 70% risk of rebleeding within one year if no secondary prophylaxis is instituted. The standard of care per Baveno VII and AASLD is combination therapy.
EVL plus NSBBs together. Combination therapy is superior to either intervention alone for preventing rebleeding. EVL sessions are repeated every 2 to 4 weeks until variceal eradication, with the first session typically performed 1 to 2 weeks after the acute bleed resolves. NSBBs (propranolol, nadolol, or carvedilol) are initiated as soon as the patient is hemodynamically stable, typically before hospital discharge.
Monitoring. After variceal eradication, surveillance endoscopy is performed every 3 to 6 months for the first year, then every 6 to 12 months. NSBB dosing is titrated to a resting heart rate of 55 to 60 bpm with systolic BP maintained above 90 mmHg. Patients should be evaluated for liver transplant candidacy, which is the definitive treatment for the underlying portal hypertension.
TIPS for secondary prophylaxis. TIPS is reserved for patients who rebleed despite combination EVL plus NSBB therapy. An HVPG reduction below 12 mmHg (or a decrease of more than 20% from baseline) after TIPS is associated with near-complete protection from rebleeding.
NCLEX priorities and clinical decision scenarios
The following decision points reflect the high-yield testing concepts for esophageal varices nursing care.
1. Airway before bleeding control. A patient with massive hematemesis and altered mental status requires intubation before endoscopy or any other intervention. Airway protection is always the first priority – the leading cause of death in the first hours of variceal hemorrhage is aspiration, not exsanguination.
2. Restrictive transfusion in variceal bleeding. The target hemoglobin is 7 g/dL. Transfusing to higher levels raises portal pressure and increases rebleeding risk. If an NCLEX question asks about transfusion threshold in a patient with GI bleeding from varices, the answer is lower than a typical surgical patient.
3. Start vasoactive drugs before endoscopy. Octreotide (or terlipressin) is started on clinical suspicion of variceal hemorrhage – do not wait for endoscopic confirmation. If a question presents a patient with known cirrhosis and hematemesis, the immediate nursing action after airway and IV access is to initiate the vasoactive infusion.
4. Beta-blocker parameters. Hold propranolol, nadolol, or carvedilol if heart rate is below 55 bpm or systolic BP is below 90 mmHg. Report these findings to the provider. NSBBs should never be initiated during an active bleed – they are for prophylaxis only.
5. Sengstaken-Blakemore tube complications. The two most tested complications are esophageal rupture (from over-inflation or prolonged placement beyond 24 hours) and airway obstruction (if the gastric balloon deflates and the tube migrates upward). The patient must be intubated. Scissors must be kept at the bedside to cut and deflate the balloon immediately if airway obstruction occurs.
6. Antibiotics are mandatory in variceal bleeding. Prophylactic antibiotics are given to every cirrhotic patient with GI bleeding – this is a standard of care, not an optional add-on. They reduce mortality, rebleeding, and bacterial peritonitis rates. If a question asks which orders to clarify on a variceal bleed patient, the absence of antibiotic orders should be questioned.
7. TIPS and encephalopathy risk. A patient who underwent TIPS placement should be monitored for new or worsening hepatic encephalopathy. Post-TIPS encephalopathy develops in 25% to 45% of patients. The nursing assessment includes orientation checks, asterixis evaluation, and lactulose/rifaximin administration.
8. Avoid NSAIDs in cirrhotic patients. Non-steroidal anti-inflammatory drugs impair platelet function and increase the risk of variceal and non-variceal bleeding in patients with cirrhosis. Acetaminophen (limited to 2 g/day in cirrhosis) is the preferred analgesic.
NANDA-I nursing care plans for esophageal varices
The five diagnoses below address the primary clinical threats in esophageal varices: hemorrhage, hemodynamic collapse, fluid deficit, psychological burden, and knowledge gaps that drive non-adherence and readmission. Each diagnosis includes esophageal-varices-specific rationale rather than generic GI guidance.
Nursing diagnosis 1: risk for bleeding
NANDA-I label: Risk for Bleeding
Related to: Elevated portal venous pressure (HVPG ≥12 mmHg), dilated thin-walled esophageal collateral vessels subject to LaPlace tension, thrombocytopenia from splenic sequestration, coagulopathy from impaired hepatic synthesis of clotting factors (II, V, VII, IX, X), and platelet dysfunction from uremia and alcohol exposure.
Risk factors (no AEB required for risk diagnoses): Child-Pugh B or C disease, MELD score above 18, large F3 varices on endoscopy, presence of red wale signs, prior variceal bleed episode, active alcohol use, NSAID or anticoagulant use, thrombocytopenia below 50,000/mcL.
| Nursing intervention | Rationale |
|---|---|
| Assess vital signs every 1–2 hours in the acute setting; immediately report heart rate above 100 bpm, systolic BP below 90 mmHg, or MAP below 65 mmHg. Target MAP 65–85 mmHg (permissive hypotension). | Tachycardia is the earliest hemodynamic sign of hemorrhagic shock. Permissive hypotension targets (MAP 65–85 mmHg) reduce variceal re-bleeding risk by limiting the pressure surge against thin-walled varices – aggressive fluid resuscitation raising MAP above 85 mmHg increases portal inflow and can precipitate re-rupture. |
| Establish and maintain two large-bore peripheral IVs (16-gauge or larger); confirm patency at every assessment. Ensure type and crossmatch, CBC, coagulation panel, and platelet count are drawn immediately on admission. | Rapid venous access is required for volume resuscitation and blood product administration. Massive variceal hemorrhage can exhaust intravascular volume within minutes; cross-matched blood must be available before the patient deteriorates further. |
| Administer octreotide per protocol: 50 mcg IV bolus, then 50 mcg/hr continuous infusion for 2–5 days. Initiate on clinical suspicion of variceal hemorrhage – do not wait for endoscopic confirmation. | Octreotide suppresses glucagon and VIP release, reducing splanchnic vasodilation and portal blood flow. Early administration before endoscopy reduces active bleeding and improves endoscopic visualization. The 5-day infusion duration reflects the highest-risk window for early re-bleeding per Baveno VII guidance. |
| Administer prophylactic antibiotics as ordered (ceftriaxone 1 g IV every 24 hours for Child-Pugh B/C; norfloxacin 400 mg PO twice daily for Child-Pugh A). Begin before endoscopy. | Bacterial infections occur in up to 50% of cirrhotic patients with GI hemorrhage and independently predict early re-bleeding and 6-week mortality. Ceftriaxone is preferred over quinolones in advanced cirrhosis due to better gram-negative coverage and high quinolone resistance rates in this population. SBP prophylaxis with ceftriaxone 1 g/day × 7 days is the Baveno VII standard. |
| Apply a restrictive transfusion strategy: transfuse packed red blood cells only when hemoglobin falls below 7 g/dL; target post-transfusion hemoglobin of 7–9 g/dL. Do not transfuse to normalize hemoglobin in stable patients. | Over-transfusion increases portal venous pressure and splanchnic blood flow, directly elevating the risk of re-bleeding. The landmark NEJM trial (Villanueva et al., 2013) demonstrated that a restrictive transfusion threshold of 7 g/dL reduced 6-week mortality compared to a liberal threshold of 9 g/dL in cirrhotic patients with acute variceal bleeding. |
| Monitor coagulation labs: platelets, INR, fibrinogen, and von Willebrand factor. Note that INR alone overestimates bleeding risk in cirrhosis because it does not capture the concurrent reduction in anticoagulant proteins (protein C, protein S). Target platelets ≥50,000/mcL before invasive procedures. | Cirrhosis produces a rebalanced hemostasis – reduced pro-coagulant factors are offset by reduced anti-coagulant proteins, so the INR misleadingly suggests higher bleeding risk than is present. Fibrinogen below 100 mg/dL is a more clinically meaningful marker of coagulopathy requiring correction. Platelet threshold of ≥50,000/mcL is the pre-procedure target for EVL per current guidelines. |
| Avoid inserting nasogastric tubes in patients with known unligated esophageal varices unless mandated by the clinical team for a specific indication. Document the decision and rationale in the chart. | Mechanical trauma from NG tube insertion against fragile variceal walls can precipitate hemorrhage. When gastric lavage or decompression is required before emergent endoscopy, the risk-benefit decision belongs to the endoscopist and intensivist with direct knowledge of variceal anatomy. |
| Prepare balloon tamponade equipment (Sengstaken-Blakemore or Minnesota tube) at the bedside for refractory hemorrhage. Ensure patient is intubated before insertion. Keep scissors taped to the head of the bed. Do not leave tube in place longer than 24 hours. | Balloon tamponade achieves hemostasis in 90% of refractory cases through direct mechanical compression of varices. Intubation is non-negotiable before insertion – unprotected airways with an inflated esophageal balloon carry near-certain aspiration risk. The 24-hour limit prevents esophageal pressure necrosis and perforation. Scissors at the bedside allow immediate balloon deflation if the gastric balloon migrates proximally and obstructs the airway. |
| Educate the patient to avoid Valsalva-type maneuvers: straining at stool, forceful coughing, vomiting without antiemetic cover, and heavy lifting. Administer stool softeners (lactulose or polyethylene glycol) for all admitted patients with varices. | Increased intra-abdominal pressure from straining transmits directly to the portal system and raises transmural variceal wall tension. Lactulose additionally targets hepatic encephalopathy prevention by reducing ammonia absorption, providing a dual benefit in this population. |
Nursing diagnosis 2: decreased cardiac output
NANDA-I label: Decreased Cardiac Output
Related to: Hemorrhagic hypovolemia secondary to acute variceal rupture, reduced preload from massive blood and fluid loss, compensatory tachycardia with decreased stroke volume, and vasodilatation from endogenous mediators (nitric oxide, prostaglandins) released in decompensated portal hypertension.
As evidenced by: Hypotension (systolic BP below 90 mmHg or MAP below 65 mmHg), tachycardia above 100 bpm, decreased urine output below 0.5 mL/kg/hr, cold and clammy skin, altered mental status, elevated lactate above 2 mmol/L, hemoglobin below threshold.
| Nursing intervention | Rationale |
|---|---|
| Monitor cardiac output indicators continuously: heart rate, blood pressure, MAP, capillary refill, skin temperature, and mental status. Reassess after every intervention. Target MAP 65–85 mmHg. | Continuous assessment detects deteriorating perfusion before irreversible end-organ damage occurs. The MAP target of 65–85 mmHg is specific to variceal hemorrhage – below 65 mmHg risks renal failure and hepatic ischemia; above 85 mmHg risks re-bleeding from elevated portal pressure. |
| Initiate cautious IV fluid resuscitation with isotonic crystalloid (normal saline or lactated Ringer's); titrate to MAP and urine output rather than a fixed volume. Avoid over-resuscitation. | Volume replacement restores cardiac preload and improves output. However, aggressive crystalloid resuscitation dilutes clotting factors and raises portal venous pressure – the goal is hemodynamic stabilization, not normalization. Lactated Ringer's is preferred over normal saline in cirrhosis to avoid hyperchloremic acidosis and worsening of renal tubular function. |
| Administer blood products per restrictive transfusion protocol (packed red blood cells; fresh frozen plasma if INR above 1.5 with active bleeding; cryoprecipitate if fibrinogen below 100 mg/dL; platelets if below 50,000/mcL pre-procedure). | Each blood product addresses a specific component of the hemostatic deficit. Packed red blood cells restore oxygen-carrying capacity. FFP and cryoprecipitate replace depleted clotting factors. Platelet transfusion ensures adequate primary hemostasis for EVL. Coordinating these interventions maximizes hemostatic effect without volume overload. |
| Position the patient flat or in modified Trendelenburg (legs elevated 10–15 degrees) during active hemorrhage; tilt to left lateral decubitus if vomiting to reduce aspiration risk. Elevate head of bed to 30–45 degrees once stabilized. | Flat positioning maximizes central venous return and cardiac preload during hypovolemic shock. Left lateral decubitus reduces aspiration risk from hematemesis by pooling gastric contents toward the stomach rather than the airway. Upright positioning post-stabilization reduces aspiration risk and aids diaphragmatic excursion. |
| Insert an indwelling urinary catheter and monitor urine output hourly. Target output above 0.5 mL/kg/hr. Report output below 30 mL/hr for two consecutive hours. | Urine output is a sensitive, real-time indicator of renal perfusion and cardiac output adequacy. Oliguria in a cirrhotic patient with variceal hemorrhage signals either ongoing hemorrhagic shock or early hepatorenal syndrome – both require immediate escalation. Hepatorenal syndrome carries greater than 90% short-term mortality without intervention. |
| Obtain 12-lead ECG and place on continuous cardiac monitoring. Report new ST changes, QTc prolongation above 500 ms, or sustained arrhythmias. | Cirrhotic patients have a high baseline prevalence of QT prolongation from electrolyte disturbances (hypokalemia, hypomagnesemia) and autonomic dysfunction. Terlipressin is associated with ischemic cardiovascular complications and arrhythmias. Octreotide can cause bradycardia and conduction abnormalities. Continuous monitoring detects complications before hemodynamic deterioration. |
| Assess lactate and base deficit at baseline and every 2–4 hours during resuscitation. Target lactate below 2 mmol/L as a resuscitation endpoint alongside MAP and urine output. | Lactate elevation above 2 mmol/L indicates cellular hypoperfusion and anaerobic metabolism – it quantifies the oxygen delivery deficit that vital signs alone may underestimate. Lactate clearance above 10% per hour correlates with improved survival in hemorrhagic shock. In cirrhotic patients, impaired hepatic lactate clearance may cause persistent elevation even after adequate resuscitation, requiring clinical correlation. |
| Coordinate urgent transfer to ICU or high-dependency unit for patients with active hemorrhage, MAP below 65 mmHg despite initial resuscitation, or MELD score above 18. | Patients with MELD above 18 and active variceal bleeding have greater than 20% six-week mortality. ICU-level monitoring with arterial line placement, central venous access, and vasopressor availability is required for patients who do not respond to initial resuscitation. Early ICU escalation reduces time to definitive therapy (TIPS). |
Nursing diagnosis 3: deficient fluid volume
NANDA-I label: Deficient Fluid Volume
Related to: Active hemorrhage from ruptured esophageal varices causing acute intravascular volume depletion, third-spacing of fluid into the peritoneal cavity (ascites) and interstitial spaces driven by hypoalbuminemia and elevated portal pressure, and renal sodium and water retention paradoxically reducing effective circulating volume.
As evidenced by: Decreased blood pressure, tachycardia, dry mucous membranes, decreased skin turgor, decreased urine output, concentrated urine (specific gravity above 1.025), elevated BUN:creatinine ratio above 20:1, weight loss with concurrent abdominal distension from ascites.
| Nursing intervention | Rationale |
|---|---|
| Weigh the patient daily at the same time with the same scale. Report a weight gain above 1 kg/day or 2 kg/week despite clinical signs of dehydration. | Daily weight is the most sensitive outpatient indicator of fluid shifts in cirrhosis. Paradoxical weight gain alongside clinical dehydration indicates third-spacing – fluid is accumulating in the peritoneal cavity (ascites) rather than remaining in effective intravascular circulation. This finding may prompt large-volume paracentesis with albumin replacement (8 g albumin per liter drained). |
| Measure and record accurate intake and output every 1–2 hours during active hemorrhage; include all blood loss from emesis, NG output, and stool. Document blood product volumes separately from crystalloid. | Quantifying all fluid losses and inputs enables precise resuscitation targeting and identifies persistent hemorrhage that may not be clinically apparent. Concealed blood loss into the GI tract from ongoing oozing may cause progressive volume depletion without overt hematemesis. |
| Monitor serum sodium closely (every 6–12 hours in acute phase). Alert the provider if sodium drops below 130 mEq/L; do not correct hyponatremia aggressively (maximum correction 8–10 mEq/L per 24 hours). | Dilutional hyponatremia is extremely common in decompensated cirrhosis due to non-osmotic ADH release triggered by reduced effective arterial blood volume. Rapid sodium correction risks osmotic demyelination syndrome (central pontine myelinolysis). Hyponatremia with sodium below 130 mEq/L is an independent predictor of 90-day mortality in cirrhosis. |
| Administer IV albumin per order (1.5 g/kg at day 1 and 1 g/kg at day 3 in patients with spontaneous bacterial peritonitis; post-large-volume paracentesis at 8 g per liter drained). Monitor for fluid overload after albumin infusion in patients with renal impairment. | Albumin expands plasma volume, maintains oncotic pressure, and has immunomodulatory effects in the inflamed cirrhotic liver. In the context of SBP – which occurs in up to 30% of cirrhotic patients with GI bleeding – albumin infusion reduces the incidence of type 1 hepatorenal syndrome from approximately 33% to 10% (Sort et al., NEJM 1999). |
| Assess for signs of ascites progression: increasing abdominal girth (measure at the umbilicus and document a reference mark), shifting dullness, fluid wave, reduced bowel sounds. Report new or worsening ascites. | Progressive ascites in the setting of acute hemorrhage may indicate worsening liver failure or SBP – both alter fluid management strategy. Abdominal compartment syndrome from tense ascites is a rare but life-threatening complication requiring urgent large-volume paracentesis. |
| Restrict dietary sodium to 2 g/day in patients with ascites; do not fluid-restrict unless serum sodium falls below 125 mEq/L. | Sodium restriction reduces renal sodium retention and limits ascites formation. The kidneys in decompensated cirrhosis retain sodium avidly due to activation of the renin-angiotensin-aldosterone system (RAAS) – limiting dietary intake is the first-line intervention before escalating to spironolactone and furosemide. Fluid restriction is reserved for severe hyponatremia and is not recommended for routine ascites management. |
| Monitor for signs of hepatorenal syndrome: rising creatinine (increase of 0.3 mg/dL above baseline within 48 hours, or doubling from baseline within 7 days), worsening oliguria, persistent hyponatremia. Report promptly; administer terlipressin or norepinephrine plus albumin per order. | Hepatorenal syndrome develops in up to 35% of hospitalized cirrhotic patients with acute variceal bleeding and carries greater than 80% short-term mortality without treatment. It results from extreme splanchnic vasodilation reducing effective renal perfusion. Early recognition and vasopressor therapy (terlipressin plus albumin is the first-line per EASL guidelines) reverses the syndrome in approximately 50% of cases. |
Nursing diagnosis 4: anxiety
NANDA-I label: Anxiety
Related to: Fear of recurrent life-threatening hemorrhage, uncertainty regarding disease prognosis and liver transplant candidacy, powerlessness over disease progression, ICU environment, and awareness that esophageal varices represent advanced liver disease with limited curative options.
As evidenced by: Verbalization of fear, restlessness, insomnia, increased heart rate and respiratory rate in the absence of bleeding, requests for repeated reassurance, refusal of procedures (EVL, TIPS), and expressions of hopelessness regarding prognosis.
| Nursing intervention | Rationale |
|---|---|
| Establish a therapeutic relationship through consistent nurse assignment and brief, frequent check-ins. Use calm, direct language and avoid rushed interactions. Address the patient by name. | Consistent nursing assignments reduce the burden of repeatedly explaining the clinical situation to unfamiliar caregivers, a major source of anxiety in ICU patients. The therapeutic relationship is the primary vehicle through which all other psychosocial interventions are delivered. |
| Explain all procedures before performing them, using plain language. Describe what the patient will see, hear, and feel – particularly for EVL, TIPS, and balloon tamponade. | Anticipatory anxiety (fear of the unknown) is often more distressing than the procedure itself. Preprocedural education reduces anxiety, improves cooperation, and reduces perceived distress. For EVL, explaining that the "tugging sensation" is normal reduces panic during banding; for TIPS, explaining the post-procedure encephalopathy monitoring reduces distress when cognitive changes occur. |
| Acknowledge the severity of the diagnosis directly while maintaining realistic hope. Discuss what is within the patient's control: NSBB adherence, alcohol abstinence, EVL scheduling, diet. | Patients with esophageal varices are aware their condition is serious – dismissing their concerns damages trust and increases anxiety by creating a mismatch between their experience and the nurse's framing. A balanced, honest approach reduces uncertainty and empowers the patient by identifying actionable steps. Perceived self-efficacy is associated with better adherence in chronic liver disease. |
| Facilitate early referral to social work, a hepatology-specific nurse navigator, and palliative care as appropriate. Ensure family participation in care conferences when the patient consents. | Esophageal varices in Child-Pugh C or MELD above 15 patients frequently necessitates goals-of-care conversations about liver transplant candidacy and resuscitation preferences. Social workers address practical barriers (financial, housing) that compound psychological distress. Palliative care reduces symptom burden and existential distress even when curative treatment continues. |
| Assess for co-existing alcohol use disorder (AUD) and facilitate addiction medicine consultation prior to discharge. Screen for depression using a validated tool (PHQ-9). | Alcohol-related cirrhosis accounts for the majority of esophageal varices in Western populations. Continued alcohol use is the single most modifiable risk factor for disease progression. Patients with AUD have a high prevalence of co-morbid anxiety and depression, both of which independently worsen adherence and quality of life. |
| Provide orientation cues in the ICU: daylight exposure, clock and calendar visibility, familiar objects from home, and minimizing overnight interruptions where clinically safe. | ICU disorientation amplifies anxiety and fear. Cirrhotic patients with subclinical or overt hepatic encephalopathy are at particularly high risk for delirium, which worsens both their anxiety and their ability to participate in care decisions. Non-pharmacologic delirium prevention through environmental orientation reduces incidence by 30–40% in general ICU populations. |
| Involve the patient in discharge planning and the EVL schedule as early as clinically appropriate. Provide a written summary of the banding plan (frequency, duration, expected eradication timeline) and the medication regimen. | Transition anxiety – fear of leaving the monitored hospital environment – is common after life-threatening hemorrhage. A concrete, written plan converts abstract uncertainty into a structured timeline with known benchmarks. Patients who understand their EVL schedule (typically 3–5 sessions over 6–10 weeks until eradication) report higher confidence managing their condition after discharge. |
Nursing diagnosis 5: deficient knowledge
NANDA-I label: Deficient Knowledge
Related to: Lack of prior exposure to esophageal varices management, complexity of multi-drug prophylaxis regimens, limited health literacy secondary to hepatic encephalopathy in some cirrhotic patients, and inadequate prior education regarding variceal surveillance and lifestyle modification.
As evidenced by: Verbalization of unawareness of variceal diagnosis, inaccurate statements about medication purpose, report of missed NSBB doses, non-adherence to EVL follow-up scheduling, continued alcohol use after diagnosis, and failure to seek timely care at onset of hematemesis.
| Nursing intervention | Rationale |
|---|---|
| Assess health literacy, cognitive status (screen for covert hepatic encephalopathy if available), and preferred learning style before beginning education. | Up to 60% of patients with cirrhosis have covert hepatic encephalopathy affecting processing speed and working memory – standard written discharge instructions may not be retained. Matching education format to literacy level and cognitive capacity maximizes comprehension. Where encephalopathy is present, include a designated caregiver in all educational sessions. |
| Teach the mechanism of NSBB therapy in plain language: "this medication lowers the pressure in the veins of your esophagus to prevent bleeding." Explain the holding parameters (HR below 55 bpm, SBP below 90 mmHg) and reinforce that stopping NSBBs abruptly dramatically increases bleed risk. | NSBB adherence is the single most impactful outpatient intervention for preventing variceal re-bleeding. Non-adherence, estimated at 30–40% in cirrhotic populations, eliminates the prophylactic benefit. Sudden NSBB discontinuation causes rebound portal hypertension and acute variceal hemorrhage. Patients who understand WHY the medication matters make more nuanced decisions than those given a simple "take this pill daily" instruction. |
| Explain the EVL schedule in concrete terms: banding every 2–4 weeks until variceal eradication (typically 3–5 sessions), then surveillance endoscopy every 3–6 months indefinitely. Provide written calendar dates at discharge. | EVL eradication requires consistent follow-through – missing sessions allows varices to recur. Patients who understand that eradication requires multiple sessions rather than a single procedure are significantly more likely to complete the course. The post-eradication surveillance interval is necessary because varices reform after obliteration in a substantial proportion of patients. |
| Teach the warning signs requiring immediate ED presentation: hematemesis (any amount of blood in vomit), large-volume black tarry stools (melena), lightheadedness or near-syncope, and rapid heart rate. Emphasize seeking care without delay. | Delay in seeking care for variceal hemorrhage is a major contributor to preventable mortality. Patients with prior variceal bleeds sometimes attempt to manage symptoms at home because the first bleed appeared to resolve spontaneously. Each re-bleed carries the same 15–25% mortality risk; early hospital presentation enables initiation of vasoactive drugs and emergent EVL in the window with highest hemostatic success rates. |
| Address alcohol abstinence explicitly and without judgment. Explain that continued alcohol use directly accelerates cirrhosis progression, increases portal pressure, and shortens time to next bleed. Provide referrals to AUD resources at every encounter. | In alcohol-related cirrhosis, sustained abstinence reduces portal pressure, slows fibrosis progression, and reduces variceal size in a proportion of patients. Six months of documented abstinence is a prerequisite for liver transplant candidacy at most centers. Framing abstinence as a doorway to transplant eligibility rather than a moral judgment is more effective for patient engagement. |
| Teach patients to avoid NSAIDs (ibuprofen, naproxen, aspirin in analgesic doses), and all non-prescribed herbal supplements without hepatology approval. Recommend acetaminophen limited to 2 g/day as the preferred analgesic. | NSAIDs impair platelet COX-1-dependent thromboxane synthesis and increase GI mucosal vulnerability, raising both variceal and non-variceal bleeding risk. Multiple herbal supplements (kava, comfrey, green tea extract) are hepatotoxic. Patients frequently underreport OTC and herbal use; explicit questioning and education is required. |
| Educate patients and caregivers on hepatic encephalopathy prevention: lactulose dosing (titrate to 2–3 soft stools daily), rifaximin indication and schedule, adequate protein intake (1.2–1.5 g/kg/day – protein restriction is outdated and harmful), and early signs of encephalopathy to report (confusion, personality change, sleep reversal, asterixis). | Variceal hemorrhage is one of the most potent precipitants of hepatic encephalopathy due to the nitrogen load from intraluminal blood breakdown. Patients with a history of encephalopathy before the bleed are at high risk for post-bleed episodes. Lactulose traps ammonia as ammonium in the colon and accelerates transit; rifaximin (550 mg twice daily) reduces ammonia-producing bacterial load. Protein restriction was historically recommended but increases sarcopenia and worsens outcomes – current EASL guidelines recommend adequate protein intake. |
| Provide written discharge materials at an appropriate reading level (sixth grade or lower). Use visual aids showing the anatomy of esophageal varices and the banding procedure where available. | Written materials extend and reinforce verbal education that may be partially retained due to anxiety, cognitive impairment, or information overload during hospitalization. Visual aids improve comprehension across all literacy levels and are particularly valuable for explaining anatomical concepts that are difficult to convey verbally. |
Frequently asked questions
What is the priority nursing intervention for a patient with esophageal varices who is bleeding?
Airway protection is the first priority. A patient with massive hematemesis or altered mental status should be assessed for intubation before any other intervention, including IV access or medication administration. Aspiration of blood is the leading cause of early death in variceal hemorrhage – once the airway is secured, the simultaneous priorities are establishing large-bore IV access, initiating octreotide infusion (50 mcg bolus, then 50 mcg/hr), and obtaining emergent endoscopy consultation.
What medications are used to treat esophageal varices?
Treatment involves two distinct phases. During acute hemorrhage, vasoactive agents – octreotide (50 mcg IV bolus, then 50 mcg/hr infusion for 2–5 days) or terlipressin (2 mg IV every 4 hours) – reduce splanchnic blood flow and portal pressure. Prophylactic antibiotics (ceftriaxone 1 g IV daily for Child-Pugh B/C) are added simultaneously. For long-term prophylaxis, non-selective beta-blockers (carvedilol 6.25–12.5 mg daily, propranolol, or nadolol) are titrated to a heart rate of 55–60 bpm.
What is the difference between primary and secondary prophylaxis for esophageal varices?
Primary prophylaxis aims to prevent the first variceal bleed using NSBBs (preferred: carvedilol per Baveno VII) or EVL for patients with medium or large varices who cannot tolerate beta-blockers. Secondary prophylaxis prevents re-bleeding after a first episode and is more aggressive: combination therapy with both EVL (every 2–4 weeks until eradication) and NSBBs together is standard, as combination therapy is superior to either intervention alone.
When is a TIPS procedure indicated for esophageal varices?
Preemptive (early) TIPS – placed within 24–72 hours of admission – is indicated for high-risk patients: Child-Pugh B with active bleeding at endoscopy, or Child-Pugh C with a score of 10–13. This approach improves 6-week and 1-year survival compared to standard EVL plus vasoactive drug therapy in this population. Rescue TIPS is used when hemorrhage is refractory to endoscopic and pharmacologic treatment. Secondary prophylaxis TIPS is reserved for patients who re-bleed despite combination EVL plus NSBB therapy.
What are the most common nursing diagnoses for esophageal varices?
The five primary NANDA-I diagnoses are: Risk for Bleeding (related to portal hypertension and coagulopathy), Decreased Cardiac Output (during active hemorrhage), Deficient Fluid Volume (from hemorrhage and third-spacing), Anxiety (from fear of recurrent life-threatening bleeding), and Deficient Knowledge (regarding NSBB adherence, EVL scheduling, warning signs, and alcohol abstinence). Risk for Bleeding is the priority diagnosis and drives the acute management protocol.
How does a nurse monitor for hepatic encephalopathy after a variceal bleed?
Post-bleed encephalopathy monitoring includes hourly neurological checks for orientation to person, place, and time; asterixis assessment (have the patient extend both arms and observe for flapping tremor – a hallmark sign); and monitoring for sleep pattern reversal (sleeping during the day, awake at night – an early sign). Lactulose is titrated to produce 2–3 soft stools daily to reduce colonic ammonia absorption. Rifaximin 550 mg twice daily is added for patients with a prior encephalopathy episode.
What are the nursing considerations for octreotide administration?
Administer the initial 50 mcg IV bolus slowly over 3–5 minutes to reduce nausea and flushing. The maintenance infusion runs at 50 mcg/hr via a dedicated IV line and should not be mixed with other medications. Monitor blood glucose every 4–6 hours – octreotide inhibits glucagon and insulin secretion, causing glucose fluctuations in both directions. Monitor for bradycardia and ST changes on the cardiac monitor. Document infusion start time accurately – the 5-day treatment window per Baveno VII begins from the time of confirmed variceal hemorrhage, not from admission.
Why is INR an unreliable bleeding predictor in cirrhosis?
The INR measures the speed of the extrinsic coagulation pathway and reflects reduced pro-coagulant factors (II, V, VII, IX, X) in cirrhosis – making it appear that cirrhotic patients are at high bleeding risk. What the INR does not capture is the simultaneous reduction in anticoagulant proteins (protein C, protein S, antithrombin III), which partially compensates for the pro-coagulant deficit. This rebalanced hemostasis means many cirrhotic patients have less net coagulopathy than the INR implies. Better markers include fibrinogen levels, platelet count, von Willebrand factor activity, and thromboelastography (TEG). A platelet count above 50,000/mcL with fibrinogen above 100 mg/dL generally provides adequate hemostasis for EVL without additional product transfusion.